New hope for rare tumors? drug axitinib tested in small trial
NCT ID NCT03839498
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests the drug axitinib in 6 adults with metastatic or inoperable pheochromocytoma or paraganglioma, rare tumors of the adrenal glands or nerve tissue. Axitinib works by blocking blood vessel growth that feeds tumors. The main goal is to see how many patients' tumors shrink or stop growing. Researchers will also track how long the disease stays under control and study genetic factors that might affect response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Axitinib (a drug that blocks blood vessel growth to tumors)
- What this could lead to
- If it works, this could point toward a new treatment option for people with rare adrenal or nerve tumors that have spread.
- What could go wrong
- This is a very small, early-phase study with only 6 participants, so results may not apply widely. The drug may not shrink tumors or could cause side effects like high blood pressure or fatigue.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARAGANGLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Columbia University Irving Medical Center
New York, New York, 10031, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a nudge in your chart unlock Life-Saving genetic clues?
- Can a radioactive 'Smart Bomb' take down resistant childhood cancers?
- Can a radioated molecule shrink untreatable neuroblastoma?
- New drug aims to shrink rare adrenal tumors
- Could a daily pill tame rare cancers in teens? new trial investigates
- Could a smartphone replace clinic visits for rare tumor survivors?